CSTL

28.61

2.03% 0.57

Handel nachbörslich: 28.61

Castle Biosciences Inc (CSTL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CSTL? Forum Prognose

Schlusskurs vom Vortag:

$28.04

Offen:

$28.18

24-Stunden-Volumen:

285.96K

Relative Volume:

0.80

Marktkapitalisierung:

$801.29M

Einnahmen:

$219.79M

Nettoeinkommen (Verlust:

$-57.47M

KGV:

-13.31

EPS:

-2.15

Netto-Cashflow:

$-19.25M

1W Leistung:

+6.63%

1M Leistung:

-7.05%

6M Leistung:

+34.64%

1J Leistung:

+37.61%

1-Tages-Spanne:

$27.58

$29.07

1-Wochen-Bereich:

$25.82

$29.07

52-Wochen-Spanne:

$16.96

$35.84

Castle Biosciences Inc Stock (CSTL) Company Profile

Firmenname

Castle Biosciences Inc

Sektor

Healthcare (1174)

Branche

Diagnostics & Research (57)

Telefon

866-788-9007

Adresse

505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX

Mitarbeiter

710

Twitter

@castlebio

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

CSTL's Discussions on Twitter

Vergleichen Sie CSTL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CSTL Castle Biosciences Inc	28.61	801.29M	219.79M	-57.47M	-19.25M	-2.15
TMO Thermo Fisher Scientific Inc	532.02	203.50B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	234.84	169.62B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	135.69	38.75B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	197.39	35.83B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	415.53	34.03B	3.84B	866.24M	792.60M	10.37

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-01-05	Eingeleitet	Scotiabank	Sector Outperform
2022-01-07	Eingeleitet	Stephens	Overweight
2021-04-30	Eingeleitet	Lake Street	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Overweight
2019-12-27	Bestätigt	Canaccord Genuity	Buy
2019-08-19	Eingeleitet	BTIG Research	Buy
2019-08-19	Eingeleitet	Canaccord Genuity	Buy
2019-08-19	Eingeleitet	Robert W. Baird	Outperform
2019-08-19	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten

Jan 03, 2025

Castle Biosciences (NASDAQ:CSTL) Given Overweight Rating at Stephens - Defense World

Jan 03, 2025

Jan 02, 2025

Castle Biosciences (NASDAQ:CSTL) Earns Overweight Rating from Stephens - MarketBeat

Jan 02, 2025

Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock - Benzinga

Jan 02, 2025

Dec 31, 2024

Brokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) PT at $39.71 - Defense World

Dec 31, 2024

Dec 29, 2024

Barclays PLC Raises Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 29, 2024

Geode Capital Management LLC Increases Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Dec 29, 2024

Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Dec 29, 2024

Dec 28, 2024

Analysts Set Castle Biosciences, Inc. (NASDAQ:CSTL) PT at $39.71 - MarketBeat

Dec 28, 2024

Dec 27, 2024

Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Holdings Lifted by Franklin Resources Inc. - MarketBeat

Dec 27, 2024

Dec 24, 2024

Castle Biosciences reports preliminary data from atopic dermatitis test study - Yahoo! Voices

Dec 24, 2024

State Street Corp Acquires 60,924 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Dec 24, 2024

Castle Biosciences to launch AD test by end of 2025 - Investing.com Canada

Dec 24, 2024

Dec 23, 2024

Castle Biosciences Unveils Promising Early Data for Revolutionary Atopic Dermatitis Test - StockTitan

Dec 23, 2024

Principal Financial Group Inc. Buys 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 23, 2024

Dec 19, 2024

Castle Biosciences CEO Derek Maetzold sells $265,357 in shares - Investing.com India

Dec 19, 2024

Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 9,364 Shares of Stock - MarketBeat

Dec 19, 2024

Castle Biosciences CEO Derek Maetzold sells $265,357 in shares By Investing.com - Investing.com South Africa

Dec 19, 2024

The True Test of Success - BOSS Magazine

Dec 19, 2024

Castle Biosciences Awards Major RSU Package to 135 Employees in Strategic Retention Move - StockTitan

Dec 19, 2024

Dec 18, 2024

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade - MSN

Dec 18, 2024

Dec 17, 2024

Castle Biosciences CEO Derek Maetzold sells $750,296 in stock - Investing.com India

Dec 17, 2024

Short Interest in Castle Biosciences, Inc. (NASDAQ:CSTL) Expands By 7.6% - MarketBeat

Dec 17, 2024

Dec 16, 2024

Captrust Financial Advisors Decreases Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Dec 16, 2024

Dec 14, 2024

Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why - MSN

Dec 14, 2024

Dec 12, 2024

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma - Business Wire

Dec 12, 2024

Dec 11, 2024

Charles Schwab Investment Management Inc. Boosts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 11, 2024

Dec 09, 2024

Castle Biosciences CEO Derek Maetzold sells $160,741 in shares - Investing.com India

Dec 09, 2024

Castle Biosciences CEO Derek Maetzold sells $160,741 in shares By Investing.com - Investing.com UK

Dec 09, 2024

Dec 07, 2024

Point72 Asset Management L.P. Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 07, 2024

Dec 06, 2024

Castle Biosciences director Daniel Bradbury sells $243,692 in stock By Investing.com - Investing.com Canada

Dec 06, 2024

Dec 05, 2024

Castle Biosciences director Daniel Bradbury sells $243,692 in stock - Investing.com India

Dec 05, 2024

Jacobs Levy Equity Management Inc. Has $14.16 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 05, 2024

Dec 04, 2024